Baillet Latour GMR

14/04/2016 11:30

The 2016 Baillet Latour Grant for Medical Research, on the theme "Infectious Diseases", has been awarded to Dr Mohamed Lamkanfi (UGent/VIB) for his project “Mechanisms of inflammasome-induced myeloid cell death and its role in host defense against bacterial pathogens”.

Since 2015 the “Baillet Latour Fund” has been awarding grants to young independent investigators to conduct medical research in Belgium.  This initiative has replaced the former InBev–Baillet Latour Prize for Clinical research and serves to encourage medical research in Belgium at a university or university hospital. This year’s grant has been awarded to professor Mohamed Lamkanfi (UGent/VIB) for his research on infectious diseases. How serious an infectious disease might be is largely determined by the inflammatory effects it generates. With his research professor Lamkanfi aims at a better understanding of the relation between infection and inflammation; this knowledge may lead to the development of methods or therapies to restrict destructive inflammatory processes to a minimum.

The laureate has been selected by the scientific jury of the Baillet Latour Health Prize. The laureate’s lab receives an annual grant of € 150.000 for the next 3 years, with a possible extension for another 2 years.

Dr. Lamkanfi has obtained his PhD from the University of Ghent in 2004, after which he has been a postdoctoral researcher in immunology at the University of Michigan (USA) and at the San Francisco based biotech company Gentech. He is currently assistant professor at UGent and VIB group leader. He got both a Starting Grant (2011) and a Consolidator Grant (2013) from ERC, as well as the Prize of the “Vlaamse Wetenschappelijke Stichting voor Biomedische Wetenschapen” (2013) and the AstraZeneca Foundation Award in Auto-immune Diseases and Rheumatology (2014).